



Building a New Public-Private Partnership for Pediatric AIDS Treatment

In 2006, an estimated 530,000 children under age 15 worldwide were newly infected with HIV. An estimated 2.3 million children under age 15 are living with HIV, and 2 million of those children live in sub-Saharan Africa. A renewed commitment to effective antiretroviral treatment (ART) of HIV infection in children is essential; without treatment, the majority of infected children die before they are three years of age.

Barriers to Meeting Children's Needs

Key obstacles to providing children in resource-limited settings with access to treatment include the following:

8 [ZUW]hYg]b X]U bcglb[< =J]bZM]cb]b]bZUbg] Traditional diagnostic tests for adults are not effective until a child is 18 months old, and technologies to improve pediatric diagnosis are not yet widely available.

< YUh WfY]bZUgf] Wi fY UbX dYfgcbY']a]U]cbg] A limited number of health clinics and trained pediatric health professionals are available to serve children infected with HIV/AIDS. Often, guidelines and other tools to facilitate prescribing ART to children are unavailable to providers.

@]a]hX]bZfa U]cb U]ci hdY]Uf]W]cglb[]fYei]fYa Ybg U]hX]ZfYbhU]g] dY]Uf]WfY]a Ybg Wb WY X]ZUW]h]c U]a]b]ghf UbX a U]b]U]b V]W] gY cZ]h Yf] complexity and other challenges associated with dosing by weight.

FY] i U]cfn]fYei]fYa Ybg] While the U.S. Government has taken steps to "fast track" approval for antiretroviral drugs (ARVs), in-country registration processes and limited infrastructure in host nations can present barriers.

: Yk Yf Zfa i U]cbg]Zf dY]Uf]W]5FJ! Of the 21 innovator ARVs approved by the Department of Health and Human Services/Food and Drug Administration (HHS/FDA) for the treatment of HIV/AIDS in adults, 12 are approved for use in children, including only 7 for children under the age of two years. Four generic ARVs in pediatric formulations have been tentatively approved to date.

H\YI "G"@YUgUB Yk DUfbYfg\]d'cb dY]Uf]W] =J #5=8G

The U.S. Government, through the U.S. President's Emergency Plan for AIDS Relief,]g Ub]ci b]W]b[] Ub i bdfYWX]bhX di V]W]df]j UY dUfbYfg\]d']c' dfca chY g]W]bh]U]W]bX technical discussions on solutions for pediatric HIV treatment, formulations and access. These partnerships seek to capitalize on the current strengths and resources of:

=bcj Ucf d Ufa U]i h]W Wa dU]Yg] in developing, producing and distributing new and improved pediatric ARV preparations;

; YbY]Wd Ufa U]i h]W Wa dU]Yg] that manufacture pediatric ARVs or have pediatric drug development programs;

H\Y I "G"; cj Yfba Ybh] in expediting regulatory review of new pediatric ARV preparations and supporting programs to address structural barriers to delivering ART to children; and

7]j] g]W]m]ta i h]U]MU'cf] U]b]n]U]cbg] to provide their expertise to support the success of the partnership.

The U.S. President's Emergency Plan for AIDS Relief is the largest commitment ever by any nation for an international health initiative dedicated to a single disease.

U.S. Department of State

U.S. Agency for International Development

U.S. Department of Defense

U.S. Department of Commerce

U.S. Department of Labor

U.S. Department of Health and Human Services

Peace Corps

**Mailing address:
SA-29, 2nd Floor
2201 C Street, NW
Washington, DC 20522-2920
www.PEPFAR.gov**

